References
- Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125–34
- Ballantyne CM, Blazing M, King TR, et al. Efficacy and safety of ezetimibe coadminstered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–94
- Jones PH, Davidson MH, Stein EA, et al. (STELLAR Study Group). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–60
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986;7:177–88
- Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101–29
- Brown WV, Bays HE, Hassman DR, et al. (Rosuvastatin Study Group). Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144: 1036
- Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89: 268–75
- Olsson AG, Istad H, Luurila O, et al. (Rosuvastatin Investigators Group). Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144: 1044–51
- Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001;8:383–90
- Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33–41
- Statistical review and evaluation clinical studies No.1 CRESTOR® (rosuvastatin calcium) tablets. Available from: http://www.fda.gov/ohrms/dockets/ac/03/slides/3968s1.htm) [last accessed 15 March 2004]
- Statistical review and evaluation clinical studies No.2 CRESTOR® (rosuvastatin calcium) tablets. Available from: http://www.fda.gov/ohrms/dockets/ac/03/slides/3968s1.htm) [last accessed 15 March 2004]
- Goldberg AC, Sapre A, Liu J, et al. Efficacy of ezetimibe 10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia. Mayo Clinic Proc 2004;79:620–9
- Feldman T, Koren M, Insull W, et al. Treatment of high risk patients with ezetimibe plus simvastatin coadministration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481–6
- Ose L, Bays H, Fraser N, et al. Efficacy and safety of the ezetimibe/simvastatin combination tablet compared to simvastatin alone in patients with primary hypercholesterolemia. Presented at 74th European Atherosclerosis Society (EAS) Congress, Seville, Spain, 17–20 April 2004
- Grundy SM, Cleeman JI, Mertz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227–39
- Gaziano J, Hebert P, Hennekens C. Cholesterol reduction: weighing the benefits and risks. Ann Intern Med 1996;124:914–8
- Gould A, Rossouw J, Stein E, et al. Cholesterol reduction yields clinical benefit. Circulation 1998;97:649–52
- VYTORIN product insert. Merck Schering Plough Pharmaceuticals, West Point, PA
- CRESTOR product insert. AstraZeneca Pharmaceuticals, Wilmington, DE